Mr. Jeffrey Carlson reports

METAVISTA3D AND BRAINBIT JOIN FORCES FOR ADVANCED CLINICAL RESEARCH

Metavista3D Inc. has entered a significant collaboration with BrainBit Inc. A 36-month memorandum of understanding has been signed by both companies, marking the beginning of an ambitious partnership aimed at pushing the boundaries of clinical research and trials. The goal is to elevate the outcomes for BrainBit's clientele by leveraging Metavista3D's enhanced 3-D display technologies.

Advancing health care through innovative display technology

The partnership is set to integrate Metavista3D's cutting-edge pseudo-holographic 3-D display technologies into BrainBit's advanced medical equipment. This collaboration is anticipated to redefine the spatial reality experiences in clinical environments while eliminating the need for stereotypical 3-D glasses. The innovative integration promises to deliver a unique visual experience, potentially transforming the way neurological and physiological data are interpreted in medical settings.

Jeff Carlson, the spokesperson for Metavista3D, expressed enthusiasm about the partnership, stating: "Collaborating with BrainBit presents a remarkable opportunity to fuse our groundbreaking 3-D technologies with pioneering medical devices. This alliance will not only enhance health care outcomes, but will also pave the way for novel applications in both medical and consumer health care sectors."

A legacy of innovation in health care technology

With a heritage spanning three decades in research and development, the Metavista3D team brings a wealth of experience in constructing equipment for professional and consumer use. Having been a major research and development force within different companies, Metavista3D has consistently aimed to innovate and create advanced solutions for both business-to-business and business-to-consumer markets. This new venture with BrainBit underscores the company's unwavering dedication to developing superior artificial-intelligence-based displays that enrich user experience across various domains.

Together, Metavista3D and BrainBit will embark on a series of clinical studies and trials, seeking to enhance the effectiveness of BrainBit's wireless EEG, EMG and ECG technologies. The combination of talents and resources from both parties anticipates groundbreaking outcomes that will significantly impact the health care industry.

This collaboration not only highlights Metavista3D's commitment to technological advancement but also its vision of integrating state-of-the-art solutions into everyday health practices. Through this alliance, a new era of visual and data accuracy in medical diagnostics is within reach, promising substantial benefits for practitioners and patients alike.

About Metavista3D Inc.

Metavista3D, through its wholly owned subsidiary, psHolix AG, is at the forefront of developing artificial-intelligence-driven, pseudo-holographic display technologies designed to transform the interaction with spatial content. With over 20 patents and a commitment to innovation, Metavista3D is shaping the future of immersive, glasses-free 3-D experiences.

Metavista3D's shares are publicly traded and listed in Canada on the TSX Venture Exchange under the ticker symbol DDD and on the German stock exchange in Frankfurt and others under the ticker symbol E3T. Metavista3D's ISIN is CA59142H1073, and its German WKN is A3EG0D.

We seek Safe Harbor.